October 2024 in “American Journal of Case Reports” Baricitinib improved hair loss and arthritis in a lupus patient.
January 2024 in “Hair transplant forum international” I'm sorry, but I can't provide a summary without the content of the document.
September 2023 in “Hair transplant forum international” I'm sorry, but I can't provide a summary without the content of the document.
July 2023 in “Hair transplant forum international” I'm sorry, but I can't provide a summary without the content of the document.
September 2011 in “Urology” The IPP index is linked to storage symptoms and leftover urine, and may help manage urinary tract symptoms.
11 citations
,
January 2021 in “British Journal of Dermatology” Mutations in the AP1B1 gene cause a new syndrome with skin, hearing, and developmental issues.
November 2018 in “Annals of oncology” A scalp-cooling system effectively prevents hair loss in breast cancer patients treated with eribulin.
8 citations
,
July 2017 in “Biochemical and biophysical research communications” A new compound, BOI, can help hair grow by changing hair cycle phases and increasing certain cell contents.
August 2020 in “Benha Journal of Applied Sciences” Higher FABP4 levels may help diagnose androgenetic alopecia early.
April 2010 in “Cancer Research” CDK4 levels affect the number of hair follicle stem cells in mice.
November 2019 in “Journal of Vertebrate Biology” QIA-64 software can measure straight wire lengths accurately but needs improvement for curved wires and width measurements.
3 citations
,
April 2025 in “American Journal of Clinical Dermatology” Baricitinib is generally safe for long-term use in treating severe alopecia areata.
April 2013 in “e-Competitions Bulletin” In 2013, the FTC settled with hair company Bosley over claims it illegally shared business information with a competitor.
60 citations
,
October 2020 in “Nature Communications” AP-1 and TGFß work together to drive resistance in basal cell carcinoma, suggesting new treatment options.
January 2018 in “Archives of general internal medicine” The document concludes that automatic biofiber hair implant is a new method for improving hair growth.
February 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
May 2021 in “FEBS open bio”
Baricitinib helped treat a man's beard hair loss when steroids didn't work.
August 2025 in “Biomedicines” Half-siblings with a rare skin condition improved with treatment for a fungal infection, but hair loss remained.
May 2010 in “Europe PMC (PubMed Central)” Near-infrared probes can safely and effectively image cysteine protease activity for disease diagnosis.
1 citations
,
April 2013 in “Journal of Investigative Dermatology” 54 citations
,
December 1999 in “Journal of Investigative Dermatology Symposium Proceedings” 1 citations
,
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.
1 citations
,
August 2021 in “Journal of Investigative Dermatology” ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.
85 citations
,
May 2009 in “Hippocampus” Progesterone helps adult male mice grow more neurons and improves memory.
August 2024 in “JAMA Dermatology” Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.
19 citations
,
May 2012 in “The journal of investigative dermatology/Journal of investigative dermatology” The type 3 IP3 receptor is important for controlling hair loss and growth.
2 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Baricitinib is a safe and effective treatment for severe alopecia areata.
September 2023 in “Journal of the American Academy of Dermatology” BAP1 mutations are rare in pediatric melanocytic tumors and may develop later in life.
11 citations
,
October 2001 in “Dermatologic Clinics” The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.